CASTLE ROCK, Colo., Aug. 28 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, today announced its common stock will begin trading on the NASDAQ Capital Markets Stock Exchange commencing with the open of trading on Tuesday, August 28, 2007. Following the close of trading on Monday August 27, 2007, AspenBio Pharma's common stock will no longer trade on the OTC Bulletin Board ("OTC BB") under the symbol "APNB." Shares will now trade under the symbol "APPY" on the NASDAQ CM.
AspenBio Pharma's CEO Richard Donnelly, said, "We are very excited with the opportunity to be listed and begin trading on NASDAQ. It would appear that the marketplace agrees with our assessment, as in the first two trading days after our initial NASDAQ listing approval announcement, our shares are up approximately 9%."
"NASDAQ is delighted that an innovative leader like AspenBio Pharma has decided to join our family of companies," said Bob McCooey, Senior Vice President of New Listings, NASDAQ's Corporate Client Group. "NASDAQ is pleased to be able to support AspenBio Pharma by providing added visibility and superior trading for the company."
About the NASDAQ
NASDAQ is the largest U.S. equities exchange operated by The Nasdaq Stock Market, Inc. . With approximately 3,200 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. It is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. NASDAQ is the primary market for trading NASDAQ-listed stocks as well as a leading liquidity pool for trading NYSE-listed stocks. NASDAQ was recently recognized as the world's premier stock exchange for data feeds for the second consecutive year. In the fifth annual Waters Rankings, readers of Waters magazine voted NASDAQ the winner of the "Best Exchange Data Feeds" award. For more information about NASDAQ, visit the NASDAQ Web site at http://www.nasdaq.com or the NASDAQ Newsroom at http://www.nasdaq.com/newsroom.
About AspenBio Pharma, Inc.
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery, development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to make exciting progress in the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients complaining of abdominal pain. For more information, please visit: http://www.aspenbiopharma.com.
Forward Looking Statements
This news release includes "forward looking statements" of AspenBio Pharma, Inc. ("APNB") as defined by the Securities and Exchange Commission (the "SEC"). All statements, other than statements of historical fact, included in the press release that address activities, events or developments that APNB believes or anticipates will or may occur in the future are forward- looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors APNB believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of APNB. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including the ability to successfully complete the development of new products, execute agreements required to successfully advance the company's objectives, retain the scientific management team to advance the products, obtain additional funding as and if needed, adverse changes in market conditions and the regulatory environment, fluctuations in sales volumes, the realization of intangible assets and meeting continued listing requirements of NASDAQ. Furthermore, APNB does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this news release should be considered in conjunction with the warnings and cautionary statements contained in APNB's recent filings with the SEC.
For more information contact: AspenBio Pharma, Inc. Greg Pusey, Chairman 303-722-4008 Investor Relations: Liolios Group, Inc. Scott Liolios or Ron Both 949-574-3860
AspenBio Pharma, Inc.CONTACT: Greg Pusey, Chairman of AspenBio Pharma, Inc., +1-303-722-4008;or, Investors, Scott Liolios or Ron Both, both of Liolios Group, Inc.,+1-949-574-3860, both for AspenBio Pharma, Inc.
